リコンビナントタンパク質＿精製したリコンビナントタンパク質 » リコンビナント成長因子 » sTRAIL R-2/TNFRSF10B, Human

sTRAIL R-2/TNFRSF10B, Human

This product is going to be discontinued.
Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling.1 The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells.2 TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.
Z02934
¥14,319.00

Ask us a question
Product Introduction
Species Human
Protein Construction
TNFRSF10B (Glu52-Ser183)
Accession # O14763
Purity > 97% as analyzed by SDS-PAGE
> 97% as analyzed by HPLC
Endotoxin Level < 1 EU/μg of protein by LAL method
Biological Activity Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/ml) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.
Expression System E. coli
Theoretical Molecular Weight 14.8 kDa
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Background
Target Background Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling.1 The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells.2 TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.
Synonyms Tumor necrosis factor receptor superfamily member 10B; Death receptor 5; TNF-related apoptosis-inducing ligand receptor 2; TRAIL receptor 2; TRAIL-R2; CD262; TNFRSF10B; DR5; KILLER; TRAILR2; TRICK2; ZTNFR9; TRICKB; TRICK2A; TRICK2B; KILLER/DR5

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.